Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) charities and (ii) other organisations working to secure UK access to new drugs for (A) incurable, (B) relapsing and (C) remitting cancers such as myeloma.

Answered by Andrew Stephenson

Department ministers and officials regularly meet with a range of organisations, with an interest in securing patient access to new cancer medicines. The National Institute for Health and Care Excellence (NICE) is the body that develops authoritative, evidence-based guidance for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits, including medicines for myeloma. The NICE aims to publish guidance on all new medicines close to the point of licensing wherever possible, and has recommended many cancer medicines for NHS use that are now available to NHS patients, including through the Cancer Drugs Fund.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she (a) has had discussions and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B) reports the impact of the modifier on approval of treatments for (1) cancers, (2) relapsing and remitting conditions and (3) conditions that are more prevalent in older people.

Answered by Andrew Stephenson

The Department regularly meets with colleagues in the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including in relation to the NICE’s methods for the evaluation of medicines. In 2022, the NICE introduced a number of changes to make its methods and processes fairer, faster, and more consistent. This includes the introduction of a broader severity modifier, in place of the end-of-life modifier. Since the changes were introduced, 79% of the NICE’s appraisals of cancer medicines carried out under the updated methods have recommended the use of the treatment for some or all of the eligible patient population, either for routine use or use through the Cancer Drugs Fund. The approval rate for all cancer appraisals carried out since 2009, when the end-of-life modifier was introduced, is 78%.

Question to the Home Office:

To ask the Secretary of State for the Home Department, how many and what proportion of visas have been granted to the non-British dependents of (a) British Israelis and (b) British Palestinians that have been repatriated since 7 October 2023.

Answered by Tom Pursglove

The Home Office publishes data on entry clearance visas in the ‘Immigration System Statistics Quarterly Release’. Data on visas granted, by nationality, main applicants, and dependants are published in table Vis_D02 of the Entry clearance detailed dataset. Information on how to use the dataset can be found in the ‘Notes’ page of the workbook. The latest data relate up to the end of 2023. Please note the published statistics do not identify how many visas were issued to dependants of people who have been repatriated since 7 October 2023.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what flexibility (a) NICE and (b) NHS England have to approve for use drugs that (i) are used in combination with other drugs, (ii) are used for various (A) conditions and (B) lines of treatment and (iii) provide significant benefits for some but not all patients; and what tools those organisations use to ensure the effectiveness of such appraisals.

Answered by Andrew Stephenson

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines, and significant licence extensions for existing medicines, should be routinely funded by the NHS. The NICE is able to recommend most new medicines for use by the NHS, including as a result of commercial agreements negotiated between NHS England and the company, in line with the commercial framework for new medicines.

The NICE develops its guidance in line with its published health technology evaluations manual, which sets out the circumstances in which its Appraisal Committees are able to apply flexibility in the evaluation of specific treatments. The NICE is, for example, able to apply a modifier in the evaluation of medicines for severe diseases that means that its committees are able to recommend medicines at a higher cost-effectiveness threshold than for less severe diseases. The NICE appraises combination therapies using the same methods that it uses for appraising single drug therapies.

Found: Resolved , That Apsana Begum and Kim Johnson be discharged from the Education Committee and Jess

Found: Jess Phillips 11R 2022– 238 Jun 2023 PCS found Member registered interest two days after the 28 day

Found: Wellingborough ) Andrew Lewer MP (Conservative, Northampton South ) Ian Mearns MP (Labour, Gateshead ) Jess

Found: Declaration of interests Jess Phillips declared her interests, in accordance with the Resolution of

Found: 2022) 20 of 22 (90.9%) Ian Mearns (Labour, Gateshead) (added 2 Mar 2020) 17 of 22 (77.3%) Jess

Found: Wellingborough ) Andrew Lewer MP (Conservative, Northampton South ) Ian Mearns MP (Labour, Gateshead ) Jess

Found: Q20 Jess Phillips: Is the level of funding enough?

Found: Wellingborough ) Andrew Lewer MP (Conservative, Northampton South ) Ian Mearns MP (Labour, Gateshead ) Jess

Found: Jess Phillips expressed her support for the amendment, and highlighted her personal experience of the

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: _NC52 Jess Phillips Apsana Begum Olivia Blake .

Found: Not called _NC45 Jess Phillips .

Found: _NC45 Jess Phillips .

Found: _NC45 Jess Phillips .

Found: Jess Phillips NC44 To move the following Clause—at end insert— “Sexual exploitation of an adult (1)

Found: _NC44 Jess Phillips .

Found: _NC44 Jess Phillips .

Found: Jess Phillips expressed her support for the amendment, and highlighted her personal experience of the

Found: Letter dated 10/05/2024 from Laura Farris MP to Jess Phillips MP regarding an issue raised in the Criminal